|By Marketwired .||
|September 3, 2014 07:30 AM EDT||
YONKERS, NY -- (Marketwired) -- 09/03/14 -- ContraFect Corporation (NASDAQ: CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer and Barry Kappel, the Company's senior vice president of business development, will present a corporate overview at the Rodman & Renshaw 16th Annual Healthcare Conference in New York, NY on Wednesday, September 10 at 9:30 AM EDT. Ms. Gregory and Dr. Kappel will discuss ContraFect's novel approach to the treatment of drug-resistant Staphylococcus aureus infections and clinical plans for its lead product, CF-301.
ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.
About Rodman & Renshaw Conferences, LLC:
The Rodman & Renshaw Annual Global Investment Conference is an informational service and networking opportunity for companies and investors. Rodman does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Rodman is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Rodman soliciting any offers to buy or sell any security of any company.
This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar references to future periods. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Jul. 26, 2016 12:45 AM EDT Reads: 620
Jul. 26, 2016 12:00 AM EDT Reads: 2,136
Jul. 26, 2016 12:00 AM EDT Reads: 1,537
Jul. 25, 2016 11:15 PM EDT Reads: 1,308
Jul. 25, 2016 11:15 PM EDT Reads: 2,011
Jul. 25, 2016 11:00 PM EDT Reads: 1,023
Jul. 25, 2016 11:00 PM EDT Reads: 1,513
Jul. 25, 2016 10:45 PM EDT Reads: 1,299
Jul. 25, 2016 10:15 PM EDT Reads: 1,677
Jul. 25, 2016 10:15 PM EDT Reads: 1,920
Jul. 25, 2016 10:00 PM EDT Reads: 1,942
Jul. 25, 2016 10:00 PM EDT Reads: 2,502
Jul. 25, 2016 08:30 PM EDT Reads: 1,934
Jul. 25, 2016 08:15 PM EDT Reads: 242
Jul. 25, 2016 08:00 PM EDT Reads: 1,917